Advaxis to Present at BIO International Convention

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. ANT
4. FFAI
5. FFR
6. LLY
7. TSLA
8. META
9. FICO
10. CART

Go back to Advaxis to Present at BIO International Convention

Advaxis (ADXS) Plans Higher-Dose ADXS-HPV Phase 1/2

June 16, 2014 8:31 AM EDT

Advaxis (NASDAQ: ADXS) announced that the Georgia Regents University (GRU) Cancer Center has received Institutional Review Board (IRB) approval to initiate a Phase 1/2 trial evaluating higher doses and repeat cycles of ADXS-HPV in patients with recurrent cervical cancer. The trial will be conducted at GRU under the direction of Dr. Samir Khleif, Director, GRU Cancer Center. ADXS-HPV is Advaxis's lead Lm-LLO cancer immunotherapy product candidate, designed to target HPV-associated cancers.

This Phase 1/2 study is designed to evaluate the safety, efficacy and immunological effect of the highest-tolerated dose of ADXS-HPV administered in repeat... More